Article
Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection.
Molecular diagnosis & therapy - 1 Oct 2014
Liu Weiwei, Hu Tingting, Chen Yuming, Zhang Xinju, Gu Xiaoye, Guan Ming
Abstract excerpt
BACKGROUND AND OBJECTIVE: JAK2 V617F mutation is a molecular marker for myeloproliferative neoplasms (MPNs). As there are no China Food and Drug Administration-approved assays for the detection of JAK2 V617F mutation in China, validation of the analytic performance of this assay is important for the clinical laboratory before its clinical implementation. We have established a method for detecting JAK2 V617F using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.